NASDAQ:ATRA Atara Biotherapeutics - ATRA News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.46 +0.33 (+6.43%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$5.20▼$5.5450-Day Range$2.85▼$5.4652-Week Range$2.83▼$16.07Volume913,883 shsAverage Volume1.08 million shsMarket Capitalization$518.04 millionP/E RatioN/ADividend YieldN/APrice Target$21.63 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRA Media Mentions By Week ATRA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATRA News Sentiment▼0.530.45▲Average Medical News Sentiment ATRA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATRA Articles This Week▼22▲ATRA Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRaymond James & Associates Has $697,000 Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)marketbeat.com - January 31 at 4:13 AMBrokerages Set Atara Biotherapeutics, Inc. (NASDAQ:ATRA) PT at $19.50americanbankingnews.com - January 28 at 3:40 AMAtara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 4 at 6:46 PMAtara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 4 at 6:46 PMAtara Biotherapeutics Gets $31M Royalty Interest Financing Deal, Shares Rise 6%marketwatch.com - December 20 at 7:40 PMAtara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royaltyfinance.yahoo.com - December 20 at 7:40 PMAnalysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Madrigal Pharmaceuticals (MDGL) and Atara Biotherapeutics (ATRA)markets.businessinsider.com - December 19 at 1:16 PMAtara Biotherapeutics' Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDbenzinga.com - December 19 at 8:16 AMAtara's Ebvallo Receives European Commission Approval For Adults And Children With EBV+ PTLDmarkets.businessinsider.com - December 19 at 8:16 AMAtara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLDfinance.yahoo.com - December 19 at 8:16 AMAtara Biotherapeutics Announces Changes to Its Board of Directorsfinance.yahoo.com - December 19 at 8:16 AMConsider Atara Biotherapeutics As The Tab-Cel Delay Resolves In The U.S.seekingalpha.com - December 17 at 8:20 AMAtara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meetingfinance.yahoo.com - December 12 at 3:57 PMAtara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conferencefinance.yahoo.com - November 23 at 8:57 AMNewsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue Forecastsfinance.yahoo.com - November 22 at 5:39 AMAtara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - November 10 at 6:46 AMAtara Biotherapeutics to Participate at the Stifel Healthcare Conferencefinance.yahoo.com - November 9 at 7:51 PMMizuho Securities Keeps Their Buy Rating on Atara Biotherapeutics (ATRA)markets.businessinsider.com - November 8 at 11:30 PMAtara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progressfinance.yahoo.com - November 8 at 6:29 PMAtara Biotherapeutics's Earnings: A Previewmsn.com - November 7 at 2:57 PMAtara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022finance.yahoo.com - November 1 at 4:50 PMAtara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022finance.yahoo.com - October 26 at 4:02 AMCHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Diseasefinance.yahoo.com - October 14 at 7:58 AMAtara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - October 10 at 5:52 PMAllogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapyfinance.yahoo.com - October 7 at 12:30 PMAcadia (ACAD) Rises More Than 14% in 3 Months: Here's Whyfinance.yahoo.com - October 6 at 4:05 PMATRA Atara Biotherapeutics, Inc.seekingalpha.com - October 1 at 3:04 PMHorizon (HZNP) Completes Enrollment in Phase IV TED Studyfinance.yahoo.com - September 30 at 11:07 AMAtara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pactmarkets.businessinsider.com - September 29 at 8:11 AMAtara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabrefinance.yahoo.com - September 28 at 7:19 PMEmergent (EBS) Acquires Worldwide Rights to Smallpox Antiviralfinance.yahoo.com - September 27 at 12:58 PMAtara Biotherapeutics, Inc. (ATRA)finance.yahoo.com - September 19 at 8:02 PMAtara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conferencefinance.yahoo.com - August 31 at 4:48 PMAeglea (AGLE) Down on Corporate Restructuring, CEO Steps Downfinance.yahoo.com - August 25 at 4:59 PMLayoffs continue as biotech companies look to rein in downturn-era costsfinance.yahoo.com - August 24 at 8:49 PMHorizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woefinance.yahoo.com - August 23 at 3:38 PMAtara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipelineseekingalpha.com - August 17 at 4:15 PMDoes Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect?finance.yahoo.com - August 15 at 9:55 PMAtara Lays Off 20% Of Its Workforce, Issues Update On Cell Therapiesfinance.yahoo.com - August 9 at 6:29 PMAtara stock rises ~27% on Q2 beat, US regulatory path for tab-cel; to cut 20% staffseekingalpha.com - August 9 at 4:43 PMAtara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2022 Results - Earnings Call Transcriptseekingalpha.com - August 8 at 10:25 PMAtara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimatesfinance.yahoo.com - August 8 at 10:25 PMAtara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Updatefinance.yahoo.com - August 8 at 5:13 PMBragar Eagel & Squire, P.C. Is Investigating TuSimple, Atara, Mercury, and the WWE and Encourages Investors to Contact the Firmapnews.com - August 5 at 11:22 PMAtara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conferencefinance.yahoo.com - August 3 at 8:39 PMHorizon (HZNP) Q2 Earnings Miss Estimates, Revenues Rise Y/Yfinance.yahoo.com - August 3 at 3:38 PMAfter Plunging 65.7% in 4 Weeks, Here's Why the Trend Might Reverse for Atara Biotherapeutics (ATRA)finance.yahoo.com - August 2 at 12:49 PMAtara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022finance.yahoo.com - August 1 at 4:13 PMDr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increasefinance.yahoo.com - July 29 at 7:20 PMINVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firmapnews.com - July 28 at 6:08 PMWhy Atara Biotherapeutics Stock Is Crashing Todayfinance.yahoo.com - July 13 at 5:35 PM Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:ATRA) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.